Study of INCB123667 in Subjects With Advanced Solid Tumors
← catalyst calendarNCT05238922 · readout in 342 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
291actual
Sites
41
Countries
France, Italy, Japan +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-05 | actual | When the study began enrolling |
| Primary completion | 2027-07-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-02-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumors
Interventions
- Drug: INCB0123667
- Drug: Palbociclib
- Drug: Bevacizumab
- Drug: Olaparib
- Drug: Paclitaxel
- Drug: Ribociclib
- Drug: Fulvestrant
Primary outcomes
what the primary-completion date above is the date OFPart 1A : Occurrence of Dose Limiting Toxicities (DLTs)
measured Up to Day 28
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
measured Up to 12 months
Number of Participants with Dose Interruptions due to TEAE
measured Up to 12 months
Number of Participants who Undergo Dose Reductions due to TEAE
measured Up to 12 months
Number of Participants Discontinue study due to TEAE
measured Up to 12 months
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed